| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Bring, Arvid, et al.
(författare)
-
Arctic terrestrial hydrology : A synthesis of processes, regional effects, and research challenges
- 2016
-
Ingår i: Journal of Geophysical Research - Biogeosciences. - 2169-8953 .- 2169-8961. ; 121:3, s. 621-649
-
Forskningsöversikt (refereegranskat)abstract
- Terrestrial hydrology is central to the Arctic system and its freshwater circulation. Water transport and water constituents vary, however, across a very diverse geography. In this paper, which is a component of the Arctic Freshwater Synthesis, we review the central freshwater processes in the terrestrial Arctic drainage and how they function and change across seven hydrophysiographical regions (Arctic tundra, boreal plains, shield, mountains, grasslands, glaciers/ice caps, and wetlands). We also highlight links between terrestrial hydrology and other components of the Arctic freshwater system. In terms of key processes, snow cover extent and duration is generally decreasing on a pan-Arctic scale, but snow depth is likely to increase in the Arctic tundra. Evapotranspiration will likely increase overall, but as it is coupled to shifts in landscape characteristics, regional changes are uncertain and may vary over time. Streamflow will generally increase with increasing precipitation, but high and low flows may decrease in some regions. Continued permafrost thaw will trigger hydrological change in multiple ways, particularly through increasing connectivity between groundwater and surface water and changing water storage in lakes and soils, which will influence exchange of moisture with the atmosphere. Other effects of hydrological change include increased risks to infrastructure and water resource planning, ecosystem shifts, and growing flows of water, nutrients, sediment, and carbon to the ocean. Coordinated efforts in monitoring, modeling, and processing studies at various scales are required to improve the understanding of change, in particular at the interfaces between hydrology, atmosphere, ecology, resources, and oceans.
|
|
| 5. |
- Tomar, AS, et al.
(författare)
-
Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging
- 2023
-
Ingår i: The British journal of ophthalmology. - : BMJ. - 1468-2079 .- 0007-1161. ; 107:1, s. 127-132
-
Tidskriftsartikel (refereegranskat)abstract
- To investigate whether the American Joint Committee on Cancer (AJCC) clinical category cT2b needs to be subclassified by the type and distribution of retinoblastoma (RB) seeding.MethodsMulticentre, international registry-based data were collected from RB centres enrolled between January 2001 and December 2013. 1054 RB eyes with vitreous or subretinal seeds from 18 ophthalmic oncology centres, in 13 countries within six continents were analysed. Local treatment failure was defined as the use of secondary enucleation or external beam radiation therapy (EBRT) and was estimated with the Kaplan-Meier method.ResultsClinical category cT2b included 1054 eyes. Median age at presentation was 16.0 months. Of these, 428 (40.6%) eyes were salvaged, and 430 (40.8%) were treated with primary and 196 (18.6%) with secondary enucleation. Of the 592 eyes that had complete data for globe salvage analysis, the distribution of seeds was focal in 143 (24.2%) and diffuse in 449 (75.8%). The 5-year Kaplan-Meier cumulative globe-salvage (without EBRT) was 78% and 49% for eyes with focal and diffuse RB seeding, respectively. Cox proportional hazards regression analysis confirmed a higher local treatment failure risk with diffuse seeds as compared with focal seeds (hazard rate: 2.8; p<0.001). There was insufficient evidence to prove or disprove an association between vitreous seed type and local treatment failure risk(p=0.06).ConclusionThis international, multicentre, registry-based analysis of RB eyes affirmed that eyes with diffuse intraocular distribution of RB seeds at diagnosis had a higher risk of local treatment failure when compared with focal seeds. Subclassification of AJCC RB category cT2b into focal vs diffuse seeds will improve prognostication for eye salvage.
|
|
| 6. |
- Zvartau, E, et al.
(författare)
-
Biological factors modulating drug reward
- 1997
-
Ingår i: BASIC AND CLINICAL SCIENCE OF MENTAL AND ADDICTIVE DISORDERS. - 0067-8147. ; :167, s. 155-161
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
